Uses
N6-Cyclopentyladenosine is a selective Adenosine A1-R agonist with Ki values of 2.3, 790 and 43 nM for human A1, A2A and A3 receptors respectively and EC50 value of 18600 nM for hA2B. It has also shown its efficacy against organophosphate toxcity.
Uses
N
6-Cyclopentyladenosine has been used to study its effect on the cavernosal smooth muscle cells from lean and db/db (obesity and type II diabetes caused by a leptin receptor mutation) mice.
Biological Activity
Potent and selective adenosine A 1 receptor agonist (K i values are 2.3, 790 and 43 nM for human A 1 , A 2A and A 3 receptors respectively; EC 50 = 18600 nM for hA 2B ). Centrally active following systemic administration in vivo .
Biochem/physiol Actions
N6-Cyclopentyladenosine (CPA) is an adenosine derivative and a potent A1 adenosine receptor agonist. It acts as an anticonvulsant and might exhibit protective actions against aminophylline (AMPH)-induced seizures.
in vivo
N6-Cyclopentyladenosine (200 nmol/kg; i.p.; single dose; 22 h before 5-fluorouracil administration) protects the hematopoietic progenitor cells (CFC-GM) in the bone marrow from the cytotoxic damage of 5-fluorouracil (HY-90006) in the 5-fluorouracil-induced hematopoietic damage model of B10CBAF1 mice[4].
N6-Cyclopentyladenosine (1 mg/kg; i.p.) suppresses rapid eye movement (REM) sleep and enhances electroencephalographic slow wave activity during non-rapid eye movement (NREM) sleep in rats[5].
N6-Cyclopentyladenosine (0.15-2.25 μmol/kg; i.p.; single dose; 30 min before training) impairs the memory retention of passive avoidance tasks in mice in a dose-dependent manner in the mouse passive avoidance behavior experiment[6].
N6-Cyclopentyladenosine (2-4 mg/kg; i.p.; single dose; 15 min before aminophylline administration) delays the onset of aminophylline-induced clonic convulsions in the mouse model of aminophylline-induced recurrent generalized seizures, but cannot prevent the death of mice within 24 h[9].
storage
Desiccate at +4°C
